Is mast cell and basophils are same?

Reading File

Finding Sources

Reading File

Mast cells and basophils are related but distinct cell types — they are not the same. Here is a detailed comparison:

Similarities (Why They Are Often Confused)

Both mast cells and basophils:

Arise from a common progenitor — the basophil–mast cell progenitor (BMCP) in the bone marrow
Express high-affinity IgE Fc receptors (FcεRI) on their surface — IgE binds to both
Degranulate when IgE-bound antigen crosslinks the receptors, releasing vasoactive mediators
Contain heparin, histamine, leukotrienes, IL-4, and IL-13 in their granules
Play central roles in allergic inflammation and anaphylaxis
Synthesize lipid mediators (LTB4, LTC4, PGD2) de novo upon stimulation

Key Differences

Feature	Mast Cells	Basophils
Origin	Hemopoietic stem cell (HSC)	Hemopoietic stem cell (HSC)
Site of differentiation	Connective tissue (migrate as immature progenitors)	Bone marrow (mature before release)
Location in body	Tissue-fixed (skin, gut, lungs) — not in circulation	Circulate in blood (0.5–1% of leukocytes)
Life span	Weeks to months	Days
Size	20–30 µm	7–10 µm
Nucleus shape	Round	Segmented (bilobed or trilobed)
Can divide?	Yes (occasionally)	No
Primary growth factors	Stem cell factor (SCF)	IL-3, GM-CSF
Main proteoglycan	Heparin, chondroitin sulfate, chondroitin sulfate E	Chondroitin sulfate A
Histamine content	Greater quantities	Lesser quantities
Neutral proteases	Present (tryptase, chymase)	Not a major feature

How They Diverge From a Common Progenitor

The BMCP diverges based on transcription factor expression:

If the BMCP expresses C/EBPα (a granulocyte-related transcription factor) → commits to become a basophil progenitor, matures in bone marrow, released into blood as mature cells
If C/EBPα is absent → BMCP migrates to the spleen, further differentiates into a mast cell progenitor (MCP), then travels to tissues (e.g., intestine) and matures there

Functional Distinction

Despite their similarities, they are triggered by overlapping but not identical stimuli. Mast cells are the primary tissue sentinels for immediate hypersensitivity reactions (Type I), while basophils are recruited from circulation during sustained allergic responses. Mast cells carry greater histamine stores and possess neutral proteases (tryptase, chymase) that basophils lack.

Bottom line: Think of them as "cousins" — same family (shared progenitor, similar granule contents, same IgE receptor), but different residences, lifespans, sizes, and roles.

— Histology: A Text and Atlas with Correlated Cell and Molecular Biology, pp. 201, 511–513, 710–711; Mulholland and Greenfield's Surgery, p. 326

Udca mechanism of action

Finding Sources

Reading File

Finding Sources

I have enough from the primary sources. Here is a comprehensive breakdown of UDCA's mechanism of action:

Ursodeoxycholic Acid (UDCA / Ursodiol) — Mechanism of Action

What is UDCA?

UDCA is a naturally occurring hydrophilic bile acid formed by bacterial epimerization of chenodeoxycholic acid in the gut. It is normally a minor constituent of the human bile acid pool (< 5%). When given therapeutically, it becomes a major biliary and plasma bile acid.

Mechanisms of Action

UDCA works through multiple complementary mechanisms:

1. Alteration of the Bile Acid Pool (Detoxification)

The normal bile acid pool is dominated by hydrophobic, cytotoxic bile acids (e.g., chenodeoxycholic acid, deoxycholic acid, lithocholic acid)
UDCA replaces and displaces these toxic hydrophobic bile acids from the pool
The result is a pool enriched with a hydrophilic, non-toxic bile acid, reducing hepatocyte injury from bile acid-induced membrane disruption

2. Reduction of Biliary Cholesterol Saturation (Litholytic Effect)

UDCA decreases biliary lipid secretion and reduces cholesterol content of bile
This makes bile less lithogenic (less likely to precipitate cholesterol gallstones)
Used clinically for dissolution of cholesterol gallstones (8–10 mg/kg/day)

3. Cytoprotection of Hepatocytes

UDCA has direct cytoprotective effects on hepatocytes
It stabilizes hepatocyte membranes against the detergent action of hydrophobic bile acids
Reduces hepatocyte apoptosis triggered by hydrophobic bile acid accumulation

4. Choleretic Effect (Stimulation of Bile Flow)

UDCA undergoes significant cholehepatic shunting: absorbed by cholangiocytes at the apical membrane → transported back to hepatocytes → resecreted into bile
This cycling stimulates biliary HCO₃⁻ secretion, Cl⁻ secretion, and fluid secretion
The net effect is increased bile flow (hypercholeresis), which helps flush toxic bile acids out of bile ducts

5. Immunomodulation

In cholestatic diseases (e.g., primary biliary cholangitis, primary sclerosing cholangitis), immune-mediated destruction of bile ducts is a key pathogenic process
UDCA has immunomodulatory effects on the immune system — the exact mechanisms are still being elucidated but contribute to its disease-modifying benefit in cholestatic liver diseases

Therapeutic Uses

Indication	Dose
Cholesterol gallstone dissolution	8–10 mg/kg/day
Gallstone prevention	300 mg twice daily
Primary biliary cholangitis (PBC)	13–15 mg/kg/day
Intrahepatic cholestasis of pregnancy (ICP)	Standard dosing

ADME Summary

Absorption: Passive diffusion in the gut
Hepatic processing: Conjugated with glycine or taurine → secreted into bile
Excretion: Primarily fecal; urinary excretion increases in cholestasis

Key Takeaway

UDCA's primary mechanism is pool replacement — flooding the bile acid pool with a non-toxic, hydrophilic acid to crowd out toxic hydrophobic acids — combined with choleresis, cytoprotection, and immunomodulation. No single mechanism explains all its benefits; it is genuinely multi-mechanistic.

— Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 1124; Yamada's Textbook of Gastroenterology, 7th ed.; Robbins & Kumar Basic Pathology

This is a shared conversation. Sign in to Orris to start your own chat.